Microba Life Sciences Caps Off Autoimmune Program with Ginko Bioworks

Microba Life Sciences (ASX:MAP) has completed an Autoimmune disease therapeutic discovery program with Boston-based Ginkgo Bioworks (NYSE:DNA) on time and within budget.

Considered the world-first microbiome therapeutic discovery effort, the program generated 3 million data points with six therapeutic leads with compelling disease-relevant activity.

Moving forward, the next steps for this program is to assess therapeutic efficacy of these 6 lead strains in disease relevant animal models and manufacturing for clinical trials.

“Autoimmune diseases represent a significant unmet need and the identification of potential live biotherapeutics is an exciting development in the creation of new modalities to improve the lives of these patients,” said SVP Trent Munro

“Broken new technical ground”

Commenting on the program, Munro stated: “Microba is at the forefront of developing precision Microbiome Therapeutics, enabled by machine learning and artificial intelligence, that have the potential to help patients in need across a number of disease indications.

“Over the past 2 years, we have broken new technical ground with this project and probed frontier biology imparted by novel microbes derived from the human gut microbiome.

“This approach has now allowed the selection of potent lead candidates that will be progressed as therapeutics.”

About Microba

Microba Life Sciences is a precision microbiome company driven to improve human health.

With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases.

Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

 

Disclaimer

JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.